Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis

Area of Science:

• Infectious Diseases
• Gastroenterology
• Pharmacology

Background:

• Increasing global resistance of Helicobacter pylori to standard first-line eradication therapies necessitates the exploration of alternative treatment regimens.
• Fluoroquinolone-based sequential therapy has emerged as a potential alternative, requiring comparative efficacy analysis.

Purpose of the Study:

• To conduct a meta-analysis comparing the efficacy of fluoroquinolone-based sequential therapy versus standard first-line treatment for H. pylori infection.

Main Methods:

• Meta-analysis of six randomized controlled trials involving treatment-naive adults infected with H. pylori.
• Comparison of fluoroquinolone-based sequential therapy (proton pump inhibitor, amoxicillin, fluoroquinolone, and metronidazole/tinidazole/furazolidone) with standard first-line therapies (standard triple or sequential therapy).

Main Results:

• The fluoroquinolone-based sequential therapy achieved a significantly higher eradication rate (87.8%) compared to standard regimens (71.1%), with a risk ratio of 1.21 (95% CI 1.09-1.35).
• Frequencies of adverse effects and treatment discontinuations due to adverse events were comparable between the fluoroquinolone-based sequential therapy and standard regimens.

Conclusions:

• Fluoroquinolone-based sequential therapy represents a reasonable and effective alternative to standard first-line eradication therapy for H. pylori infections.
• The efficacy of H. pylori eradication appears consistent across trials regardless of therapy duration or fluoroquinolone dosage.